MME and hydrops fetalis: In clinical practice, pharmacological agents that enhance the biological actions of this peptide, such as nesiritide, neprilysin inhibitors, or more recently, the angiotensin receptor antagonist-neprilysin inhibitor LCZ696, have shown potential for translational research to improve HF patient care [6,7].